Headache and Migraine

The review period for the oral CGRP receptor antagonist has been set at 10 months, with a Prescription Drug User Fee Act action date in the fourth quarter of 2019.

Neurology News Network for the week of March 9, 2019.

This young woman is otherwise healthy and doesn’t drink or abuse drugs. What’s in your differential diagnosis?

Studies have suggested that exercise may have short- and long-term analgesic effects on migraine. New information has come to light about which type of exercise is best.

The patient has a history of migraine. Is this another attack-or is something else going on?

The 23rd FDA commissioner’s resignation is effective in about a month; his successor has not yet been named.

If approved, galcanezumab would be the first preventive option approved for patients with episodic cluster headache in the United States.

A driver sees what appear to be squiggly lines in the right field of vision of her right eye.

The pediatric critical care medicine attending physician in the Department of Anesthesiology and Critical Care Medicine at the Children’s Hospital of Philadelphia spoke about how physicians can better address brain death in pediatric patients.

If approved, eptinezumab, an Alder Biopharmaceuticals product, would become the fourth member of the CGRP class, and the only member available for quarterly infusions.

The framework consists of 2 documents that expand on the agency’s plans for its risk-based approach for describing drugs, devices, and biologics, including those designated as regenerative medicine advanced therapies.

As many patients with migraine and other disorders are resistant to currently available options, this increase in device development has brought forward additional path­ways to treatment for patients.

In this podcast, Dr Heidi Moawad interviews a neurologist currently researching new, available treatments in headache medicine.

Find concise summaries of the latest management recommendations and research findings in this brief highlights slideshow.

The phase 2 trial for the CGRP receptor agonist is planned for Q2 of 2019 after the intranasal treatment met its target therapeutic exposures in phase 1. Biohaven submitted an IND to the FDA in September 2018.

The Director of the Jefferson Headache Center spoke about migraine therapies that hold excitement and promise in the new year.

The acute administration of adhesive dermally applied microarray zolmitriptan (Qytripta, Zosano Pharma) showed an almost uniform benefit across subgroups of patients with severe pain, delayed treatment, nausea, and who were awakening with headache.

The mist-like nasal spray acts rapidly and is well tolerated and is formulated using Intravail to achieve blood levels similar to a 4-mg sumatriptan subcutaneous injection, resulting in rapid onset of action.

The director of the MedStar Georgetown University Hospital Headache Center discussed the importance of understanding the biologic mechanisms of migraine for patients and providers.

A recent review of the ICER report on calcitonin gene-related peptide inhibitor monoclonal antibodies has suggested that due to their cost and comparative benefit to available treatments, they should be reserved as second-line treatments.

Neurology News Network for the week of January 19, 2019.

The American Headache Society President spoke with NeurologyLive about the recent AHS position statement on the use of migraine treatments in clinical practice

The guidance provided the society’s recommendations for the use of the newly approved calcitonin gene-related peptide monoclonal antibodies for the prevention of migraine, among other guidance points.

The AAN position statement author further addressed the opposing position of the Nevada law, the AAN’s position on brain death, and what clinicians need to know in regard to determining it.

The Chair of the AAN’s Ethics, Law and Humanities Committee spoke to the American Academy of Neurology’s goal to improve the consistency of determining brain death.